Low-Dose Azacitidine Plus Venetoclax Is Effective Maintenance for AML | Blood Cancers Today
Low-dose azacitidine plus venetoclax was a feasible maintenance regimen in AML after intensive or low-intensity induction therapy.
Low-dose azacitidine plus venetoclax was a feasible maintenance regimen in AML after intensive or low-intensity induction therapy.
In this study, Dr. Shilpa Gupta and colleagues examined patient-reported outcomes from the landmark EV-302 trial.
Episodic future thinking may help breast cancer survivors lose weight.
When used in combination with trastuzumab and pertuzumab, eribulin is noninferior to trastuzumab and pertuzumab plus taxane in treating HER2-positive breast cancer.
A recent study in BMC Medicine found that type 2 diabetes significantly increases the risk of various cancers, with the risk being even higher in…
Breaking Data Presented at ASCO 2024 Showcase Breadth of The Leukemia & Lymphoma Society Therapy Acceleration Program Impact on Key Blood Cancer Research > Page…
Investigators validated two substitute markers that predicted treatment effect on eight-year progression-free survival among patients with extranodal marginal zone lymphoma.
In this presentation, Bill Faloon described many recent developments in age-reversal technologies to an audience on May 1st, 2024. Topics covered include the…
First Look With ASCO Daily News presents Dr. Matt Galsky on the results of a post hoc analysis of CheckMate-901 (Abstract 4509) on responses to…
Oregon authorities have closed the state’s entire coastline to mussel harvesting due to an “unprecedented” outbreak of shellfish poisoning that has sickened at least 20…
The former mayor of Mexico City, who is Jewish, is victorious over previous head of state in historic results heralding Mexico’s first woman president; She…